The present invention provides a way to capture a biomolecule such as a protein in one or more layers of covalently bonded amorphous silica, forming a cage or shell which preserves the shape of the protein and prevents denaturation caused by heat and/or aging and/or non-physiological conditions, through unfolding and loss of secondary and/or higher order structure.

The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.

The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.

Provided herein is a solid dispersion, which comprises a carrier and an active ingredient. The active ingredient is one or more of the compound shown in formula (I) (APG-115), its pharmaceutically acceptable salt, its crystal form and its hydrate. The solid dispersion can improve the dissolution of the active ingredient APG-115. The dissolution of APG-115 of some solid dispersions can reach more than 90%, and has good stability. It can improve the dissolution and dissolution of drugs in gastrointestinal fluid, so as to improve the oral bioavailability. The solid dispersion shows high plasma exposure in animals, that is, higher drug peak concentration and higher area under blood concentration curve.

##STR00001##

The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

The present invention comprises compositions comprising therapeutically effective amounts of CBD and curcumin in various combinations to treat pain. CBD and curcumin are preferably from natural sources. A method of using the combination of CBD and curcumin compositions to treat pain is also described.

The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

The present invention relates to a pharmaceutical composition for oral use comprising therapeutically effective amount of otilonium bromide in combination with therapeutically effective amount of simethicone, wherein the composition possesses certain bulk density and improved dissolution characteristics. Wherein a final blend prior to compression has a bulk density of at least 0.35 g/mL, and at least 85% of the otilonium bromide is released in 15 minutes in each of 0.1 N HCl, pH 4.5 and pH 6.8 buffer solutions at 370.5 C. using USP type II (paddle) apparatus rotating at 50 rpm.

An effervescent chewable dosage form that comprises a pH neutralization agent, an acid, and an effervescent agent. The chewable dosage form can also further comprise simethicone, a sweetener, and a lubricant. The pH neutralization agent can be calcium carbonate, the acid can be citric acid and the effervescent agent can be sodium bicarbonate.

Disclosed are a phenylephrine hydrochloride-containing tablet, a preparation method and use. The method for preparing a phenylephrine hydrochloride-containing tablet includes: mixing a granule A with other granules to be uniform to obtain a mixture, and subjecting the mixture to tablet pressing to obtain the phenylephrine hydrochloride-containing tablet; wherein the granule A is prepared by dry granulation, and contains phenylephrine hydrochloride as a single active pharmaceutically ingredient, the other granules comprise at least one selected from the group consisting of a granule B and a granule C, and the granule B contains acetaminophen as an active pharmaceutical ingredient, and the granule C contains dextromethorphan hydrobromide and chlorpheniramine maleate as active pharmaceutical ingredients.